Name: Latest research reports of Laurus Labs Ltd. authored by BOB Capital Markets Ltd. and published by - Trendlyne research reports.
Item: Laurus Labs Ltd.
Rating: 5
Author: BOB Capital Markets Ltd.

Laurus Labs Ltd.

NSE: LAURUSLABS | BSE: 540222 | ISIN: INE947Q01028 | Industry: Pharmaceuticals
| Strong Performer, Getting Expensive

895.6000 -0.80 (-0.09%)

NSE Sep 11, 2025 15:31 PM

Near 52W High of ₹922.50

Volume: 724.4K

Laurus Labs Ltd.

19 Aug 2020

895.60

-0.09%

Pharmaceuticals: Expensive e-pharmacy deals; Neutral impact for pharma majors

Buy: Laurus Labs Ltd.

BOB Capital Markets Ltd.

Media articles suggest growing consolidation in the e-pharmacy chain, i.e. Reliance-Netmeds and PharmEasy-Medlife.

Laurus Labs Ltd. has gained 60.21% in the last 6 Months